Your session is about to expire
← Back to Search
Penicillin Antibiotic
1 for Healthy Subjects
N/A
Waitlist Available
Research Sponsored by Ranbaxy Laboratories Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and GlaxoSmithKline (Augmentin®) 400 mg amoxicillin (as the trihydrate) and 57 mg clavulnic acid (as the potassium salt) chewable tablet, following administration of 2 tablet dose under fed conditions
Eligible Conditions
- Healthy Subjects
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: 1Experimental Treatment1 Intervention
Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets of Ranbaxy
Group II: 2Active Control1 Intervention
Augumentin chewable tablets of Glaxosmithkline
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amoxicillin
FDA approved
Find a Location
Who is running the clinical trial?
Ranbaxy Laboratories LimitedLead Sponsor
100 Previous Clinical Trials
4,042 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger